Hyperfine, Inc.
HYPR Healthcare Medical Devices
Hyperfine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 5.22% from fiscal 2024. In the quarter to June 2026, revenue grew 44.8%, EPS grew 25.0% and free cash flow grew 13.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow HYPR
Hyperfine, Inc. (HYPR) Altman Z-score
Hyperfine, Inc.'s Altman Z-score for fiscal 2025 is −6.11, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −6.11 | (1.70) |
| FY2024 | −4.41 | (4.98) |
| FY2023 | 0.57 | 0.02 |
| FY2022 | 0.55 | 0.48 |
| FY2021 | 0.07 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.71 | — | 0.85 | |
| Retained earnings / total assets | (5.97) | — | −8.36 | |
| EBIT / total assets | (0.67) | — | −2.21 | |
| Market value of equity / total liabilities | 5.62 | — | 3.37 | |
| Sales / total assets | 0.25 | — | 0.25 | |
| Altman Z-score | Distress zone | −6.11 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −16.31 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| APYX Apyx Medical Corporation compare | 1.1× |
| ZOMDF Zomedica Corp. compare | 0.4× |
| SERA Sera Prognostics, Inc. compare | −2.1× |
| LNSR LENSAR, Inc. compare | −2.8× |
| LUNG Pulmonx Corporation compare | −4.8× |
| OM Outset Medical, Inc. compare | −5.4× |
| HYPR Hyperfine, Inc. | −6.1× |
| LUCD Lucid Diagnostics Inc. compare | −10.9× |
| ECOR electroCore, Inc. compare | −13.5× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets